Shock Exchange
Contributor since: 2012
Company: New york shock exchange
Latest Articles
Gilead: Novartis's Kymriah Is Coming To America
Valeant: The Xifaxan Killer Could Arrive In November
Sell Target Into Earnings
Urban Outfitters Earnings Preview
AutoZone Earnings Preview
Walmart Is  Running In Quicksand
Intel Delivers
Endo Keeps Hope Alive
Will 'Public Shaming' Sink Celgene?
Esmya Restriction In Europe Could Handcuff Allergan
The Jury's Still Out On Depomed
Valeant: Much Ado About Nothing
A Buvaya Failure Could Sting Insys
Botox Knock-Off Could Change Fortunes For Evolus
Mallinckrodt: Appeals Court Rules Inomax Patent Invalid
Walmart Earnings Preview
Teva's Generic Restasis Could Punish Allergan
Generic Revlimid Could Sink Celgene
Insys Continues To Tread Water
Mallinckrodt: Acthar Continues To Crack
Evolus: Is The Botox Knock Off Finally Here?
Will Mullets Bail Out Allergan?
Celgene And Otezla Are Cracking
Teva: It Will Get Worse
Allergan's Growth Is Really Dead
Depomed Earnings Preview
Insys Earnings Preview
Gilead: What A Disaster
FDA Finds Mallinckrodt's Supplemental NDA For Amitiza Lacking
AbbVie: Can Mylan Pull Off A Humira Biosimilar?
Apple Stymies Qualcomm's Quarterly Results
Endo Pharmaceuticals Earnings Preview